Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of BMS-986419 (Part 1) and the effects of multiple doses of BMS-986419 on cardiac repolarization (Part 2) in healthy participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part 1: Administration of BMS-986419 | Experimental |
| |
| Part 1: Administration of Placebo | Placebo Comparator |
| |
| Part 2: Group 1 | Experimental |
| |
| Part 2: Group 2a | Experimental |
| |
| Part 2: Group 2b | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-986419 | Drug | Specified dose on specified days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Part 1: Number of Participants with Non-serious Adverse Events (NSAEs) | Up to approximately Day 42 | |
| Part 1: Number of Participants with Serious Adverse Events (SAEs) | Up to approximately Day 42 | |
| Part 1: Number of Participants with AEs Leading to Discontinuation | Up to approximately Day 42 | |
| Part 1: Number of Participants With AEs of Special Interest (AESI) | Up to approximately Day 42 | |
| Part 1: Number of Participants With Clinically Significant Vital Sign Abnormalities | Vital sign parameters include temperature, systolic blood pressure (BP), diastolic BP, respiratory rate, and heart rate (HR) assessment. | Up to approximately Day 21 |
| Part 1: Number of Participants With Clinically Significant Laboratory Assessment Abnormalities | Up to approximately Day 21 | |
| Part 1: Number of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities | Up to approximately Day 21 | |
| Part 1: Number of Participants With Clinically Significant Columbia-Suicide Severity Rating Scale (C-SSRS) Abnormalities | Up to approximately Day 21 | |
| Part 1: Number of Participants With Clinically Significant Neurological Examination Abnormalities |
| Measure | Description | Time Frame |
|---|---|---|
| Part 1: Maximum Observed Plasma Concentration (Cmax) of BMS-986419 | Up to approximately Day 21 | |
| Part 1: Time of Maximum Plasma Observed Concentration (Tmax) of BMS-986419 | Up to approximately Day 21 |
Not provided
Inclusion Criteria
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Celerion | Tempe | Arizona | 85283 | United States |
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
| BMS Clinical Trial Patient Recruiting | View source |
Not provided
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
See plan description
See plan description
Not provided
Not provided
Not provided
Not provided
Not provided
| BMS-986419 Matching Placebo | Drug | Specified dose on specified days |
|
| Moxifloxacin | Drug | Specified dose on specified days |
|
| Moxifloxacin Matching Placebo | Drug | Specified dose on specified days |
|
| Up to approximately Day 21 |
| Part 1: Number of Participants With Physical Examination Abnormalities | Up to approximately Day 21 |
| Part 2: ΔQTc: Change From Baseline in Plasma Concentration of BMS-986419 on Cardiac Repolarization Expressed by QT interval (QTc) | ΔQTc is performed by primary correction. | Up to approximately Day 15 |
| Part 2: ΔΔQTc: Placebo-corrected Change From Baseline QTc Plasma Concentration of BMS-986419 on Cardiac Repolarization Expressed by QTc | Up to approximately Day 15 |
| Part 1: Area Under the Concentration-time Curve in One Dosing Interval (AUC(TAU)) of BMS-986419 | Up to approximately Day 21 |
| Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC [0-T]) of BMS-986419 | Up to approximately Day 21 |
| Part 1: Terminal Phase Elimination Half-life (T-Half) of BMS-986419 | Up to approximately Day 21 |
| Part 1: Accumulation Index; Ratio of Cmax at Steady-state to Cmax After the First Dose (AI_Cmax) of BMS-986419 | Up to approximately Day 21 |
| Part 1: Accumulation Index; Ratio of AUC(TAU) at Steady-state to AUC(TAU) After the First Dose [AI_AUC(TAU)] of BMS-986419 | Up to approximately Day 21 |
| Part 1: Apparent Total Body Clearance (CLT/F) of BMS-986419 | Up to approximately Day 21 |
| Part 1: Apparent Volume of Distribution of Terminal Phase (Vz/F) of BMS-986419 | Up to approximately Day 21 |
| Part 1: Trough Concentration of BMS-986419 | Up to approximately Day 21 |
| Part 2: ΔQTc of BMS-986419 Using Change From Baseline of Heart Rate (HR)(ΔHR) Correction | Up to approximately Day 15 |
| Part 2: ΔQTc of BMS-986419 Using Change From Baseline of Pulse Rate (PR)(ΔPR) Correction | Up to approximately Day 15 |
| Part 2: ΔQTc of BMS-986419 Using Change From Baseline of Respiratory Rate (RR) Interval Correction | Up to approximately Day 15 |
| Part 2: Change From Baseline of BMS-986419 in Quality Rating System (QRS) Interval (ΔQRS) | Up to approximately Day 15 |
| Part 2: Number of Participants With Treatment-emergent Values of Fridericia's Corrected QT interval (QTcF) for BMS-986419 | Participants with increase in absolute treatment-emergent QTc values >450 and ≤480 milliseconds (msec), >480 and ≤500 msec, or >500 msec, and changes from pre-dose baseline of >30 and ≤ 60 msec, or >60 msec will be measured. | Up to approximately Day 15 |
| Part 2: Number of Timepoints With Change in Absolute Treatment-emergent QTcF Values for BMS-986419 | Number of timepoints with increase in absolute treatment-emergent QTc values >450 and ≤480 milliseconds (msec), >480 and ≤500 msec, or >500 msec, and changes from pre-dose baseline of >30 and ≤ 60 msec, or >60 msec will be measured. | Up to approximately Day 15 |
| Part 2: Number of Participants With Treatment-emergent Values of Individualized Heart Rate-corrected Interval/Optimized HR-corrected QT Interval (QTcS/QTcI) for BMS-986419 | Up to approximately Day 15 |
| Part 2: Number of Participants With Treatment-emergent Values of HR for BMS-986419 | Participants with decrease in HR from pre-dose baseline >25% to a HR <50 beats per minute (bpm); and increase in HR from pre-dose baseline >25% to a HR >100 bpm will be determined. | Up to approximately Day 15 |
| Part 2: Number of Timepoints With Change in Absolute Treatment-emergent HR Values for BMS-986419 | Number of timepoints with decrease in HR from pre-dose baseline >25% to a HR <50 beats per minute (bpm); and increase in HR from pre-dose baseline >25% to a HR >100 bpm will be determined. | Up to approximately Day 15 |
| Part 2: Number of Participants With Treatment-emergent Values of PR for BMS-986419 | Participants with increase in PR from pre-dose baseline >25% to a PR>200 msec will be determined. | Up to approximately Day 15 |
| Part 2: Number of Timepoints With Increase in Absolute Treatment-emergent PR Values for BMS-986419 | Number of timepoints with increase in PR from pre-dose baseline >25% to a PR>200 msec will be determined. | Up to approximately Day 15 |
| Part 2: Number of Participants With Treatment-emergent Values of QRS for BMS-986419 | Participants with increase in QRS from pre-dose baseline >25% to a QRS >120 msec will be determined. | Up to approximately Day 15 |
| Part 2: Number of Timepoints With Increase in Absolute Treatment-emergent QRS Values for BMS-986419 | Number of timepoints with increase in QRS from pre-dose baseline >25% to a QRS >120 msec will be determined. | Up to approximately Day 15 |
| Part 2: Number of Participants With New Onset ECG Morphology Findings | "New" means an ECG finding that is not present on any baseline ECG [that is, any ECG recorded prior to receipt of the first dose of study BMS-986419] and becomes present on at least 1 on-treatment ECG during that treatment period). | Up to approximately Day 15 |
| Part 2: ΔQTc: Change From Baseline in Plasma Concentration of Moxifloxacin on Cardiac Repolarization Expressed by QT interval (QTc) | ΔQTc is performed by primary correction. | Up to approximately Day 15 |
| Part 2: ΔΔQTc: Placebo-corrected Change From Baseline QTc Plasma Concentration of Moxifloxacin on Cardiac Repolarization Expressed by QTc | Up to approximately Day 15 |
| Part 2: Number of Participants with NSAEs | Up to approximately Day 36 |
| Part 2: Number of Participants with SAEs | Up to approximately Day 36 |
| Part 2: Number of Participants with AEs Leading to Discontinuation | Up to approximately Day 36 |
| Part 2: Number of Participants With AESI | Up to approximately Day 36 |
| Part 2: Number of Participants With Clinically Significant Vital Sign Abnormalities | Vital sign parameters include temperature, systolic BP, diastolic BP, respiratory rate, and HR assessment. | Up to approximately Day 15 |
| Part 2: Number of Participants With Clinically Significant Laboratory Assessment Abnormalities | Up to approximately Day 14 |
| Part 2: Number of Participants With Clinically Significant 12-Lead ECG Abnormalities | Up to approximately Day 15 |
| Part 2: Number of Participants With Clinically Significant C-SSRS Abnormalities | Up to approximately Day 15 |
| Part 2: Number of Participants With Clinically Significant Neurological Examination Abnormalities | Up to approximately Day 15 |
| Part 2: Number of Participants With Physical Examination Abnormalities | Up to approximately Day 15 |
| Part 2: Cmax of BMS-986419 | Up to approximately Day 15 |
| Part 2: Tmax of BMS-986419 | Up to approximately Day 15 |
| Part 2: AUC(0-T) of BMS-986419 | Up to approximately Day 15 |
| Part 2: AUC(TAU) of BMS-986419 | Up to approximately Day 15 |
| Part 2: T-Half of BMS-986419 | Up to approximately Day 15 |
| Part 2: AI_Cmax of BMS-986419 | Up to approximately Day 15 |
| Part 2: AI_AUC(TAU) of BMS-986419 | Up to approximately Day 15 |
| Part 2: Trough Concentration of BMS-986419 | Up to approximately Day 15 |
| ID | Term |
|---|---|
| D000077266 | Moxifloxacin |
| ID | Term |
|---|---|
| D024841 | Fluoroquinolones |
| D042462 | 4-Quinolones |
| D015363 | Quinolones |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided